Shabnam Gupta, MD
Nephrology · Livingston, NJNPI 1427097039
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.7% of the total across 315 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations.
Across 315 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Vifor Pharma, Inc.$658
- Bayer$614
- Amgen$520
- Otsuka America Pharmaceutical, Inc.$424
- Ardelyx, Inc.$267
- plus $2K from 28 others
What the payments were for
- Consulting fees$1152%
- Food & beverage$5,42194%
- Education$2474%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 64 | $1,195 |
| Vifor Pharma, Inc. | 57 | $658 |
| Bayer | 30 | $614 |
| Amgen | 31 | $520 |
| Otsuka America Pharmaceutical, Inc. | 17 | $424 |
| Ardelyx, Inc. | 10 | $267 |
| Mallinckrodt Hospital Products Inc. | 12 | $249 |
| Novo Nordisk | 15 | $218 |
| Travere Therapeutics, Inc. | 8 | $192 |
| Calliditas Therapeutics US Inc. | 10 | $159 |
| AbbVie | 9 | $149 |
| Fresenius USA Marketing, Inc. | 2 | $141 |
| Medtronic | 1 | $141 |
| ANI Pharmaceuticals, Inc. | 6 | $100 |
| OPKO Pharmaceuticals, LLC | 6 | $89 |
| Akebia Therapeutics Inc | 4 | $83 |
| Novartis | 5 | $82 |
| Boehringer Ingelheim | 5 | $80 |
| Boston Scientific | 1 | $76 |
| GSK | 5 | $68 |
| Arbor Pharmaceuticals, Inc. | 3 | $38 |
| Myovant Sciences Inc. | 1 | $36 |
| Lilly USA, LLC | 2 | $32 |
| Astellas Pharma US Inc | 1 | $24 |
| Aurinia Pharma U.S., Inc. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Nevro Corp. | 1 | $17 |
| Shire North American Group Inc | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
| Avion Pharmaceuticals | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Bard Peripheral Vascular, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,783 in reported general payments places this provider in the 85th percentile of 413 nephrology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 83 | $91,819 |
| OzempicSemaglutide | 61 | $69,354 |
| KerendiaFinerenone | 36 | $38,921 |
| JardianceEmpagliflozin | 16 | $21,707 |
| ProcritEpoetin Alfa | 13 | $19,096 |
| JanuviaSitagliptin Phosphate | 11 | $17,487 |
| VeltassaPatiromer Calcium Sorbitex | 16 | $16,883 |
| Sevelamer Carbonate | 46 | $15,354 |
| TrulicityDulaglutide | 11 | $10,140 |
| Cinacalcet Hcl | 16 | $4,746 |
| Febuxostat | 17 | $2,895 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 24 | $1,400 |
| Losartan Potassium | 106 | $1,397 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 14 | $1,189 |
| Calcium Acetate | 15 | $1,163 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $1,195 | $91,81983 claims |
| Novo NordiskOzempic | $218 | $69,35461 claims |
| BayerKerendia | $614 | $38,92136 claims |
| Boehringer IngelheimJardiance | $80 | $21,70716 claims |
| Lilly USA, LLCTrulicity | $32 | $10,14011 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $100 | $1,07725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 413 nephrology providers in New Jersey.
Other nephrology in Livingston
- Lawrence ByrdLivingston$338K
- Robert SipznerLivingston$5K
- Jeffrey FeldmanUnion$315K
- Joshua KaplanNewark$154K
- Vadim FinkielsteinPrinceton Junction$139K
- Neeraj SinghNew Brunswick$133K
- Harry DounisNeptune$75K
- Kenneth LissEatontown$75K
- Jeffrey GoodmanFlorham Park$70K
- Arif AsifNeptune$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.